1. Wilhelminen Cancer Research Institute, Department of Medicine I, Center for Oncology and Hematology, Wilhelminen Hospital, Vienna, Austria;
2. Department of Hematology, University of Leipzig, Leipzig, Germany;
3. Division of Hematology and Medical Oncology, Department of Internal Medicine II, Wuerzburg University Medical Center, Wuerzburg, Germany;
4. Department of Internal Medicine III with Haematology, Medical Oncology, Hemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute – Center for Clinical Cancer and Immunology Trials, Cancer Cluster Salzburg, Austria;
5. CCRC Cancer Clinical Research Consulting, Düsseldorf, Germany;
6. Department of Medicine I, Center for Oncology and Hematology, Wilhelminen Hospital, Vienna, Austria;
7. Department of Medicine I, Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz Elisabethinen, Linz, Austria;
8. Fakultní Nemocnice Ostrava, Ostrava, Czech Republic;
9. Department of Internal Medicine V, Hematology and Oncology, Medical University Innsbruck, Innsbruck, Austria;
10. Department of Internal Medicine I, Ordensklinikum Linz – Barmherzige Schwestern, Linz, Austria;
11. University Medical Center of Hamburg-Eppendorf, Hamburg, Germany;
12. Oncotyrol, Center for Personalized Cancer Medicine, Innsbruck, Austria;
13. Department of Oncology, Hematology and Gastroenterology, Academic Teaching Hospital Feldkirch, Feldkirch, Austria;
14. Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic;
15. Department of Internal Medicine 3, Kepler Universitaetsklinikum GmbH, Med. Campus III, Linz, Austria;
16. Medical Department, Division of Psychosomatic Medicine, Charité- Universitätsmedizin, Berlin, Germany